Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 July 2022 | Story Andre Damons | Photo Supplied
Prof Martie Smith and Prof Drik Opperman
Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.

Flavours and fragrances have a wide application in the food, feed, cosmetic, chemical and pharmaceutical sectors. Many flavour compounds are still produced via chemical synthesis or via extraction from plant or animal sources. However, there is increasing interest in their bio-production or the use of flavour compounds of (micro) biological origin. 

One reason for this shift is that chemical synthesis often uses environmentally unfriendly processes. Chemical synthesis usually also produces racemic mixtures with the second enantiomer, mirror image of the looked-for compound, often having undesirable organoleptic properties. Furthermore, the consumer has developed a “chemophobia”-attitude towards synthetic chemical compounds, especially when related to food and home-care products.  This applies even to nature-identical compounds – products that occur in nature but are produced via a non-natural chemical process. Products produced with the use of enzymes or microbes from “natural” substrates can be labelled “natural”. The flavour and fragrance industry thus pay higher prices for such products labelled as “natural”.  

The invention

A University of the Free State (UFS) team, led by Prof Martie Smit and Prof Dirk Opperman in the Department of Microbiology and Biochemistry are conducting exciting research in this area. They filed a patent entitled “Process for the chemical modification of alkanes, fatty acids and fatty alcohols”.  

The invention relates to a process for the enzymatic in-chain hydroxylation of C12 to C16 fatty acids, alcohols, and alkanes. Hydroxylation of C12 fatty acid and alcohol provides routes for the synthesis of “natural” δ-dodecalactone. The advantage of these routes is that they do not rely on massoia lactones. Massoia lactones are derived from the bark of Massoia trees which grow in Indonesia. Harvesting of the bark kills the trees.  

The cytochrome P450 enzymes (P450s) claimed in this patent are to the inventors’ knowledge the most regioselective enzymes described thus far that can be used for the synthesis of δ-dodecalactone from lauric acid or 1-dodecanol. The approach that the technology takes is to claim cytochrome P450 enzymes that share 70 % amino acid identity to a set of selected P450s for the regioselective hydroxylation of lauric acid and 1-dodecanol to synthesise δ-dodecalactone.

Still in early stage

The current state of development is early stage with the technology only demonstrated in the laboratory on a small scale (100-200 ml). Before the technology can be commercialised the team would need to further improve the regioselectivity and stability of the P450s and proof that the reactions can be scaled up in bioreactors. The technology will probably be delivered as an enzyme (amino acid sequence) with the desired properties. 

There are other research groups working on a synthetic biology approach for the de novo synthesis of δ-dodecalactone from glucose by genetically engineered microbes. It is still unclear how such a process will compare in terms of product yields, economics and environmental impact with the processes proposed by the UFS patent.

If the team had to partner with a commercial company, their first choice would be to work with an established flavour and fragrance company. Another possibility would be the small French flavour and fragrance company that Dr Alizé Pennec, the post-doc and co-inventor who initially discovered the unique P450 activity, is working for.

Please view the videos for more information on patents.

The Vice-Rector: Research and Internationalisation has released two new calls for applications for funding. Academic staff and researchers are encouraged to submit applications for these funds. At this stage we are not accepting projects from Research Fellows. 

The two funds are: 

1.  The Industrial Engagement Fund 
2.  The Intellectual Property Commercialisation Fund

Each fund has its own guidelines and application process. The guidelines are attached. The applications must be filled in on RIMS.

The RIMS application forms can be found through this link

For more information please click the documents below:



News Archive

Cochlear implant changes Magteld's world
2009-11-06

The microphone is ready for Magteld Smith’s (second from the left) first radio interview after the cochlear implant was switched on by Mr Henk Wolmarans (right) of MedEl. With them are, from the left: Ms Vicki Fourie, Deaf Miss SA, Ms Eunika Smith from the SABC and Prof. Jonathan Jansen.
Photo: Leatitia Pienaar


Magteld Smith gave her first steps towards the world of the hearing when her cochlear implant was switched on in the Universitas Hospital this week.

A whole team was there to share her joy and disbelief and amazement the moment she could hear noises, voices and conversations. Among them were the Rector and Vice-Chancellor of the University of the Free State (UFS), Prof. Jonathan Jansen, and the acting dean of the Faculty of Heath Sciences at the UFS, Prof. Gert van Zyl.

“I can hear my own voice! I haven’t heard it for a long time. My wish is that every deaf child can get something like this,” she said while prodding Prof. Jansen to speak so that she can hear his voice.

Magteld is working at the university's Centre for Health Systems Research and Development and was deaf since birth. She lost her last bit of hearing due to meningitis last year. Her hearing aids could then not assist her to communicate and a cochlear implant was the only option.

A donation by the Austrian company MedEl made the implant possible. Prof. André Claassen, Head of the Department of Otorhinolaryngology at the UFS, says MedEl was also instrumental in the establishment of the implant programme at the Universitas Hospital and sponsored the first five implants at a total cost of R1 million.

Prof. Claassen says 27 implants have already been done here, but it came to an abrupt halt due to a lack of funds. Strong hearing aids are expensive and cochlear implants are even more expensive at R200 000 each. People with hearing disabilities must be identified at an early age as the brain’s ability to learn sound and voice diminishes after the age of three.
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept